The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1165
September 15, 2003
View Complete Issue         Table of Contents 2019 
Agalsidase beta (Fabrazyme) for Fabry Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Agalsidase beta (Fabrazyme) for Fabry Disease
September 15, 2003 (Issue: 1165)
Agalsidase beta (Fabrazyme Genzyme) has received accelerated approval from the FDA for treatment of patients with Fabry disease, an inherited lysosomal storage disease caused by deficiency of α-galactosidase A. Agalsidase beta is a...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Agalsidase beta (Fabrazyme) for Fabry Disease
Article code: 1165b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.